摘要
目的:探讨尼莫地平合用生脉注射液治疗早产儿颅内出血的临床疗效。方法:138例患儿随机分为对照组(n=60)和治疗组(n=78),治疗组在治疗早产儿各项并发症的基础上加用尼莫地平和生脉注射液,动态观察其有效率、存活率,脑积水、脑室旁白质软化、智力低下和脑瘫的发生率。结果:①对照组显效25.0%、有效30%、有效率55%,治疗组显效33.3%、有效44.8%、有效率78.1%(χ2=14.6,P<0.01);②存活率对照组为75.5%、治疗组为88.5%(χ2=4.7,P<0.05);③脑积水的发生率,对照组为37.7%,治疗组为8.7%(χ2=14.3,P<0.01);④脑室旁白质软化的发生率,对照组为37.8%,治疗组为18.5%(χ2=5.0,P<0.05);⑤智力低下的发生率,对照组为33.0%,治疗组为8.7%(χ2=11.0,P<0.01);⑥脑瘫的发生率,对照组为17.0%,治疗组为4.3%(χ2=5.4,P<0.05)。结论:尼莫地平、生脉注射液联合应用治疗早产儿颅内出血,可以提高存活率、减少并发症和后遗症,改善预后。
Objective： To observe the clinical efficacy of nimodipine conjoin pulse activating injection on pretmature intracranial hemorrhage. Methods： One hundred and thirty-eight patients who had intracranial hemorrhage were randomly divided into the treatment group（ n = 78） and the control group（ n = 60）. The complications were positively treated, and also the treatment group accepted nimodipine conjoin pulse activating injection. The effective rate, mortality, occurrence of hydrocephalus, peri-ventricular leucomalacia, mental retardation and cerebral palsy were observed. Results： The efficacy of the treatment group （78.1% ） was better than that of the control group （55.0%） （P 〈 0.01）. The mortality and the occurrence rate of hydrocephalus, peri-ventricular leucomalacia, mental retardation and cerebral palsy of the treatment group were respectively 11.5 %, 8.7 %, 18.5 %, 8.7 % and 4.3 %, which were all significantly lower than those of the control group： 25.0%, 37.7%, 37.8%, 33.0% and 17.0% （ P 〈 0.05 or P 〈 0.01）. Conclusions： Nimodipine conjoin pulse activating injection is a safe and effective method for premature intracranial hemorrhage. It cannot only reduce the mortality, but also decreases the complications and sequela.
出处
《山东大学学报（医学版）》
CAS
北大核心
2007年第5期538-540,共3页
Journal of Shandong University:Health Sciences
关键词
颅内出血
婴儿
早产
尼莫地平
生脉注射液
Intracranial hemorrhages
Infant, premature
Nimodipine
Pulse activating injection
